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Genome-wide association studies have revealed >60 loci associated with type 2 diabetes (T2D), but the under-
lying causal variants and functional mechanisms remain largely elusive. Although variants in TCF7L2 confer
the strongest risk of T2D among common variants by presumed effects on islet function, the molecular
mechanisms are not yet well understood. Using RNA-sequencing, we have identified a TCF7L2-regulated tran-
scriptional network responsible for its effect on insulin secretion in rodent and human pancreatic islets. ISL1
is a primary target of TCF7L2 and regulates proinsulin production and processing via MAFA, PDX1, NKX6.1,
PCSK1, PCSK2 and SLC30A8, thereby providing evidence for a coordinated regulation of insulin production
and processing. The risk T-allele of rs7903146 was associated with increased TCF7L2 expression, and
decreased insulin content and secretion. Using gene expression profiles of 66 human pancreatic islets
donors’, we also show that the identified TCF7L2-ISL1 transcriptional network is regulated in a genotype-
dependent manner. Taken together, these results demonstrate that not only synthesis of proinsulin is regu-
lated by TCF7L2 but also processing and possibly clearance of proinsulin and insulin. These multiple targets
in key pathways may explain why TCF7L2 has emerged as the gene showing one of the strongest associations
with T2D.
INTRODUCTION
TCF7L2 harbors common genetic variants with the strongest
effect on type 2 diabetes (T2D) risk yet described, i.e. the single-
nucleotide polymorphism (SNP rs7903146) (1–3). TCF7L2 is a
transcription factor (TF) in the Wnt-signaling pathway and
expressed in many tissues including fat, liver and pancreatic
islets of Langerhans (4). A majority of risk variants associated
with T2D by GWAS seem to affect islet function (5,6). In con-
cordance, the risk T-allele of rs7903146 is associated with
impaired glucose-stimulated insulin secretion (GSIS) or other
secretagogues-like GLP-1 (2,7–12). Risk T-allele carriers are
further characterized by an elevated plasma proinsulin level
and an increased proinsulin-to-insulin ratio suggestive of per-
turbed proinsulin processing (13–21). In support of a primary
effect in pancreatic islets, the risk T-allele carriers show higher
degree of open chromatin in pancreatic islets, but not in other
tissues (22). Several mouse models of Tcf7l2 have been investi-
gated (23–28), but the diabetic phenotype has not been repli-
cated in all studies. Experiments in rodent islets where
TCF7L2 activity has been disrupted have usually demonstrated
impaired GSIS (11,29,30).
∗To whom correspondence should be addressed at: Department of Clinical Science, Endocrinology and Diabetes, Lund University, Ing 72, Building 91,
Fl 12, Sweden. Tel: +46-391228; Fax: +46-391222; Email: Ola.Hansson@med.lu.se
# The Author 2014. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
Human Molecular Genetics, 2014, Vol. 23, No. 24 6419–6431
doi:10.1093/hmg/ddu359
Advance Access published on July 11, 2014
Paradoxically, carriers of the risk T-allele show increased ex-
pression of TCF7L2 in human pancreatic islets (7,31). Plasmid
construct carrying the risk T-allele, when compared with those
with the C-allele, displayed a much stronger transcriptional
activity, implying a higher enhancer activity of the T-allele
(22,32). TCF7L2 may act both as a stimulator and a repressor
of gene expression due to both differential splicing and inter-
action with different co-regulators in target gene recognition
(33). However, the target genes of TCF7L2 in pancreatic islets
or B-cells have not been described in detail. Our aim was to iden-
tify TCF7L2-target genes in pancreatic islets and to describe the
regulatory network downstream of TCF7L2 responsible for its
influence on insulin secretion.
RESULTS
Tcf7l2 influences insulin synthesis and secretion
Impaired in vivo (7) and in vitro (9,31) insulin secretion has been
shown in risk T-allele carriers of rs7903146. We have replicated
and extended these findings in pancreatic islets from human non-
diabetic cadaver donors (n ¼ 75, Fig. 1A; Supplementary Ma-
terial, Table S3). We also show reduced insulin content (27%)
in risk T-allele carriers (n ¼ 81, Fig. 1B), and that TCF7L2
mRNA expression is 16% higher than C-allele carriers (n ¼
66;RNA-seq, Fig. 1C).Further,TCF7L2expression is negatively
associated with proinsulin expression in human islets in C-allele
carriers (n ¼ 36), but not in T-allele carriers (n ¼ 30, Fig. 1D;
Supplementary Material, Table S3).
Silencing Tcf7l2 in a rat insulinoma cell line (INS1 832/13)
using siRNA targeting the invariable exon 1, resulted in 84%
knockdown of Tcf7l2mRNA, 90% reduction of TCF7L2 activity
and a reduced expression of the well-known TCF7L2-target genes
Axin2 andCcnd1 (Supplementary Material, Fig. S1A and B) (30).
The decrease inTcf7l2 resulted in a marked reduction of GSIS, i.e.
1.76-fold (Tcf7l2 silencing,P. 0.05) versus 6.97-fold (controls,
P, 0.05, Fig. 1E) and a perturbed glucose-stimulated proinsulin
secretion (GSPS) (P, 0.05, Fig. 1F). Proinsulin-to-insulin ratio
was higher under glucose stimulation compared with basal condi-
tion in Tcf7l2 silenced cells (P, 0.05, Fig. 1G) suggesting per-
turbed proinsulin processing. Immunohistochemistry (IHC)
analysis of Tcf7l2 silenced INS1 cells showed reduced staining
intensity for insulin (P, 0.001) and VAMP2 (P, 0.001), a
marker of insulin-containing granules, in Tcf7l2 silenced cells
(Fig. 1H). Furthermore, there was a reduction in insulin-
containing granules close to the plasma membrane as assessed
by total internal reflection fluorescence (TIRF) microscopy
(P, 0.05, Fig. 1I). Together, these data suggest that TCF7L2
mediates key aspects of insulin production, processing and intra-
cellular trafficking.
Identification of TCF7L2-target genes influencing insulin
synthesis and secretion
The molecular mechanisms underlying these findings are not
clear, but an altered expression of TCF7L2-target genes is likely
part of the explanation. To identify genes regulated by TCF7L2
in B-cells, we screened for global differential expression using
RNA-seq in Tcf7l2 silenced INS1 cells versus scramble-treated
control. Overall, 10779 genes were actively expressed (.30
aligned paired-end reads per gene, corresponding to .10
FPKM); 1680 genes were upregulated and 1885 genes were
downregulated in Tcf7l2 silenced cells (5% false discovery rate,
FDR, n ¼ 4). Among the most differentially expressed genes
were Il6r,Aldh1a1andSrp14, but none of these has a known func-
tion in insulin secretion. Genetic variation in the IL6R-locus has
been weakly associated with T2D (34), but this was not replicated
(35) or supported by recent GWAS findings (21,36–42); there-
fore, Il6r was not studied further. Instead we categorized genes
known to influence GSIS into three groups: (i) glucose sensing,
(ii) proinsulin expression and maturation and (iii) exocytotic ma-
chinery (genes differentially regulated in the RNAseq screen are
reported in Table 1). In addition, genes located proximal to
SNPs with replicated associations to T2D and/or plasma proinsu-
lin were also selected for further analysis (Supplementary Mater-
ial, Table S2). Real-time quantitative PCR (QPCR) confirmed the
RNA-seq results for many of the tested genes (Table 1), i.e. 18 out
of 29 analyzed genes were replicated in independent samples at
the mRNA level. To confirm these findings at the protein level,
a selected set of 15 genes (with mRNA change .30%) was ana-
lyzedusingwesternblot,with11geneshaving significant changes
(Supplementary Material, Table S3, the complete list of 3565
potential target gene can be found in the Supplementary Material,
Table S6).
Tcf7l2 is a key regulator of proinsulin production
and processing
Twelve analyzed genes involved in proinsulin synthesis were
downregulated in Tcf7l2 silenced cells, including proinsulin
genes Ins1 and Ins2 (Table 1 and Fig. 2A). The reduction of all
but one (Cpe) was confirmed using QPCR. The protein encoded
by the Ins1 and Ins2 genes was decreased in Tcf7l2 silenced
cells (Fig. 2A). We next replicated this finding in primary cells
by measuring proinsulin protein expression in a Tcf7l2 homozy-
gous null mouse model (Tcf7l22/2) (26). Notably, proinsulin ex-
pression was reduced by 85% (n ¼ 6) in pancreas fromTcf7l22/2
mice (postnatal day 0; P0) compared with wild-type mice
(Fig. 2B). Given differences in the insulin gene between rodents
and humans (43), we also replicated the findings in human
pancreatic islets showing 49% reduced proinsulin mRNA ex-
pression after TCF7L2 silencing (n ¼ 5, Fig. 2C).
In the processing of proinsulin to insulin, the endoprotease
prohormone convertase 1/3 (PCSK1) and prohormone conver-
tase 2 (PCSK2) cleave the proinsulin molecule to yield mature
insulin and C-peptide. We found reduced mRNA expression
levels of both Pcsk1 and Pcsk2 in the RNA-seq screen of
Tcf7l2 silenced INS1 cells (Table 1). This result was confirmed
using QPCR and at the protein level in INS1 cells (Fig. 2A). No
significant change in PCSK1 and PCSK2 protein expression was
observed in theTcf7l22/2mouse pancreas (Fig. 2B). InTCF7L2
silenced human pancreatic islets, PCSK1 and PCSK2 mRNA
expression was reduced by 36 and 49%, respectively (Fig. 2C).
Tcf7l2 is not a major regulator of genes involved
in the exocytotic machinery or glucose sensing
Of the 11 genes categorized as involved in the exocytotic ma-
chinery, mRNA expression of Cacna1a, Cana1c, Cacna1d and
Cacnb3 was reduced in Tcf7l2 silenced cells (Table 1;
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Figure 1. The type 2 diabetes-associated SNP rs7903146 and TCF7L2 expression influences insulin synthesis and secretion. (A) GSIS in human islets (CC: n ¼ 44,
CT/TT:n ¼ 31). (B) Insulin content in human islets (CC:n ¼ 45, CT/TT:n ¼ 36). (C)TCF7L2mRNAexpressionmeasured by RNA-seq in human islets (CC:n ¼ 36,
CT/TT:n ¼ 30). (D) Expression (mRNA) of INS andTCF7L2 in human islets measured by RNA-seq stratified for rs7903146 genotype (CC: n ¼ 36, CT/TT: n ¼ 30).
(E) GSIS in INS1 cells afterTcf7l2 silencing. (F) GSPS in INS1 cells afterTcf7l2 silencing. (G) Proinsulin-to-insulin ratio in INS1 cells afterTcf7l2 silencing. (H) IHC
staining of insulin and VAMP2 in INS1 cells afterTcf7l2 silencing. (I) Amount of insulin-containing granules measured by TIRF microscopy in INS1 cells afterTcf7l2
silencing. Data are represented as mean+SEM. In (A)–(D), data were analyzed by linear regression with correction for age, gender and BMI. In (E)–(I), 2.8 versus
16.7 mM glucose were analyzed by paired Student’s t-tests, Tcf7l2 silencing versus controls by unpaired Student’s t-tests with n ¼ 3. ∗P, 0.05, ∗∗P , 0.01 and
∗∗∗P, 0.001 (Supplementary Material, Tables S1 and S4).
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Supplementary Material, Fig. S1C). However, this was not con-
firmed at the protein level for Cav2.1, Cav1.2 or Cav1.3, either
72 h or 7 days after Tcf7l2 silencing (Supplementary Material,
Fig. S1D and E). RNA expression of two out of the five genes
involved in glucose sensing (Glud1 and Slc2a2/Glut2) was
reduced at the mRNA level in Tcf7l2 silenced cells (Table 1),
and GLUD1 protein expression was measured but no change
was observed (Supplementary Material, Fig. S1F).
Tcf7l2 is regulating proinsulin expression directly via Isl1,
Ins1 and indirectly viaMafA, NeuroD1 and Pdx1
After establishing that TCF7L2 is a regulator of proinsulin ex-
pression and maturation, we investigated by which molecular
mechanism this may occur. For this purpose, we interrogated
the RNA-seq results for genes differentially expressed
between Tcf7l2 silenced INS1 and control cells. Intriguingly,
ISL LIM homeobox 1 (Isl1), v-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog A (MafA), pancreatic and
duodenal homeobox 1 (Pdx1), neuronal differentiation 1
(NeuroD1), NK6 homeobox 1 (Nkx6.1) and NK2 homeobox 2
(Nkx2.2) were all expressed at lower levels in Tcf7l2 silenced
cells (Table 1). All observations, except the NKX2.2 protein,
were confirmed using QPCR and western blot (Fig. 3A). The re-
duction of ISL1 and NEUROD1 was further confirmed using
IHC (Supplementary Material, Fig. S1G and H). These results
were confirmed in Tcf7l22/2 mice, with protein levels reduced
relative to wild-type mice for ISL1, MAFA and NEUROD1
(Fig. 3B). Likewise, after TCF7L2 silencing in human islets, ex-
pression of most transcripts was downregulated, including ISL1,
MAFA,PDX1,NEUROD1 andNKX6.1 (Fig. 3C). In addition, in
islets from CC-genotype carriers of rs7903146, TCF7L2mRNA
expression was negatively associated with that of ISL1, MAFA
and NKX6.1 but not for MAFA and NKX6.1 in CT/TT-risk-
genotype carriers (Supplementary Material, Table S4). The
disruption of Tcf7l2 resulted in a marked reduction in GSIS
compared with controls 1.93- (P. 0.05) versus 4.10-fold
(P , 0.05) increases (Fig. 3D). The same was observed after
disruption of Isl1, MafA and NeuroD1 (Fig. 3D).
To delineate the proinsulin regulatory cascade among the
identified TCF7L2-target genes, Isl1, MafA, Pdx1, NeuroD1
and Nkx6.1 were sequentially silenced in INS1 cells using
siRNA. First, knocking down Isl1 reduced both the mRNA and
protein expression of MafA, Pdx1, Nkx6.1, Pcsk1, Pcsk2, Ins1
and Ins2 (Fig. 4A). No effect of Isl1 knockdown was observed
Table 1. mRNA expression of selected genes influencing GSIS measured using RNA sequencing (RNAseq) in Tcf7l2 depleted INS1 832/13 cells versus scrambled
control, with replication in independent experiments using real-time QPCR
Gene symbol Gene ID RNAseq QPCR
LogFC P-value corrected LogFC P-value
Glucose sensing Glud1 ENSRNOG00000010222 20.7143 7.15E207 20.8681 4.97E203
Slc2a2 ENSRNOG00000011875 20.5864 9.20E206 20.4150 2.68E203
Gck ENSRNOG00000015024 21.1232 6.26E204 20.0145 0.9905
G6pc ENSRNOG00000036806 0.3828 7.80E204 N/A N/A
Mpc1 ENSRNOG00000012415 20.4338 2.00E203 N/A N/A
Exocytotic machinery Cacna1a ENSRNOG00000002559 21.0612 2.71E212 21.5564 6.52E204
Syt5 ENSRNOG00000018217 20.9024 2.46E210 20.4739 4.24E202
Stxbp1 ENSRNOG00000015420 20.6269 5.93E206 20.3401 4.51E202
Cacna1d ENSRNOG00000013147 20.6143 1.89E205 21.0893 1.88E202
Cacna1c ENSRNOG00000007090 20.7861 2.10E205 20.8625 2.20E203
Cacnb3 ENSRNOG00000012489 20.5654 6.67E204 21.0000 4.00E204
Stx1a ENSRNOG00000029165 0.5308 5.10E204 20.0145 0.8288
Snap25 ENSRNOG00000006037 20.4135 3.49E203 20.2863 0.2271
Syt9 ENSRNOG00000019613 20.4048 1.28E202 20.3219 0.0597
Cacnb1 ENSRNOG00000004518 0.6164 2.76E202 20.0589 0.6316
Vamp2 ENSRNOG00000006989 20.2960 3.29E202 20.2176 0.2964
Proinsulin production and maturation Slc30a8 ENSRNOG00000004747 21.4601 1.08E215 20.8365 8.80E203
NeuroD1 ENSRNOG00000005609 21.1931 9.73E214 21.2176 3.17E203
Cpe ENSRNOG00000043387 21.4682 3.16E209 20.3040 0.1358
Isl1 ENSRNOG00000012556 21.1075 1.23E207 21.3585 7.40E204
Ins1 ENSRNOG00000012052 21.1761 5.38E207 21.3959 1.40E202
Pcsk2 ENSRNOG00000005438 20.8951 9.81E206 20.6897 4.56E202
Nkx6.1 ENSRNOG00000002149 20.6335 7.70E205 20.5995 9.26E204
Pcsk1 ENSRNOG00000011107 20.7932 8.45E205 20.7859 3.45E203
Nkx2.2 ENSRNOG00000012728 21.0863 4.18E203 20.8021 2.30E202
Ins2 ENSRNOG00000020405 20.9005 5.11E203 21.0893 1.35E202
MafA ENSRNOG00000007668 21.1927 4.61E202 22.1844 2.96E203
Pax4 ENSRNOG00000008020 2.9857a 4.75E202 N/A N/A
Pdx1 ENSRNOG00000046458 N/Ab N/Ab 20.8110 2.19E202
N/A, not analyzed using QPCR; LogFC, the logarithm of fold change, i.e. Tcf7l2 depleted/scrambled control; the P-value for RNAseq was corrected by FDR 5%.
P-value for QPCR was calculated using Student’s t-tests; N ¼ 4 (RNAseq), N ¼ 3 (QPCR).
aVery low expression.
bPdx1 was not aligned in the RNA-seq analysis.
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on Tcf7l2 or NeuroD1 mRNA expression (Fig. 4A). Previously,
we have analyzed chromatin immunoprecipitation on tiling
array (ChIP-on-Chip) using a TCF7L2 antibody identifying
both the Isl1 and Ins1 promoters as directly bound by TCF7L2
(30). Together, these data indicate that Isl1 is a direct primary
target gene for TCF7L2 and regulates proinsulin expression
and processing via Isl1-dependent regulation of MafA, Pdx1,
Nkx6.1, Pcsk1 and Pcsk2. In human islets, ISL1 expression is
positively associated in C-allele carriers with that of MAFA,
PDX1, NKX6.1, INS and SLC30A8 but in T-allele carriers only
with PDX1 and NKX6.1 (Supplementary Material, Table S4).
Knocking down MafA reduced mRNA expression of Nkx6.1,
Nkx2.2, Pcsk2, Ins1 and Ins2. These changes were confirmed at
the protein level for all but NKX6.1 and NKX2.2 (Fig. 4B). In
human islets, MAFA expression was positively associated with
proinsulin gene expression both in C- and T-allele carriers (Sup-
plementary Material, Table S4). Knocking down Pdx1 reduced
the mRNA expression of MafA, Nkx6.1, Nkx2.2, Pcsk2, Ins1
and Ins2. These changes were confirmed at the protein level
for all but PCSK2 (Fig. 4C). Knocking down NeuroD1
reduced the mRNA expression of Tcf7l2, Isl1, MafA, Pdx1,
Nkx6.1, Nkx2.2, Pcsk1, Pcsk2, Ins1 and Ins2. This was,
Figure2.TCF7L2 is a key regulator of proinsulin production and processing. (A) mRNA expression measured by QPCR in INS1 cells inTcf7l2 silenced versus control
cells (n ¼ 3). Protein expression measured by western blot in INS1 cells in Tcf7l2 silenced versus control cells (n ¼ 3). (B) Protein expression measured by western
blot inTcf7l2 allele-null versus wild-type mice (n ¼ 6). (C) mRNA expression measured by QPCR in human pancreatic islets inTCF7L2 silenced versus control islets
(n ¼ 3–5). Data are represented as mean+SEM. ∗P, 0.05, ∗∗P , 0.01 and ∗∗∗P , 0.001 analyzed by Student’s t-tests (Supplementary Material, Table S1).
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Figure3.TCF7L2 is regulating proinsulin expression via direct regulation of ISL1 and indirectly via MAFA, NEUROD1 and PDX1. (A) mRNA expression measured
by QPCR in INS1 cells inTcf7l2 silenced versus control cells, (n ¼ 3). Proteinexpressionmeasured by western blot in INS1 cells inTcf7l2 silenced versus control cells,
(n ¼ 3). (B) Protein expression measured by western blot in Tcf7l2 allele-null versus wild-type mice (n ¼ 6). (C) mRNA expression measured by QPCR in human
pancreatic islets inTcf7l2 silenced versus control cells, (n ¼ 3). (D) GSIS in INS1 cells afterTcf7l2, Isl1,MafA andNeuroD1 silencing (n ¼ 3). Data are represented as
mean+SEM. ∗P , 0.05, ∗∗P, 0.01 and ∗∗∗P, 0.001 analyzed in (A)–(C) by unpaired Student’s t-tests. In (D), 2.8 versus 16.7 mM glucose were analyzed by
paired Student’s t-tests (Supplementary Material, Table S1).
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however, not reflected by changes in the ISL1, MAFA and PDX1
protein levels (Fig. 4D). Knocking down Nkx6.1 reduced the
mRNA expression of Tcf7l2, Isl1, MafA, Pdx1, Nkx6.1,
Nkx2.2, Pcsk2, Ins1 and Ins2. At the protein level, we could
only confirm the reduction of MAFA and proinsulin (Fig. 4E).
In summary, these data together with previous ChIP-on-Chip
results (30) indicate that ISL1 is a direct target of TCF7L2 and
that ISL1, in turn regulates proinsulin production and processing
via regulation of MAFA, PDX1, NKX6.1, PCSK1 and PCSK2
expression.
Figure 4. Sequential silencing of TCF7L2-target genes in the proinsulin regulatory cascade. mRNA and protein expression after: (A) Isl1, (B) MafA, (C) Pdx1,
(D) NeuroD1 and (E) Nkx6.1 silencing versus controls measured by QPCR and western blot in INS1 cells. Data are represented as mean+SEM. ∗P , 0.05,
∗∗P, 0.01 and ∗∗∗P , 0.001 analyzed by Student’s t-tests with n ¼ 3 (Supplementary Material, Table S1).
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TCF7L2 is a transcriptional regulator of key genes located
in T2D-associated loci
Next, we examined whether silencing of Tcf7l2 was associated
with changes in expression of rat orthologs of putative genes
in T2D-associated loci (36,37,41,44–46) (Supplementary Ma-
terial, Table S2). We observed differential mRNA expression
for 23 genes, 17 out of these were replicated using QPCR and
3 at the protein level (i.e. Slc30a8, Ide and Bcl11a) (Figs 2 and
5). Of note, Tcf7l2 silencing in INS1 cells led to a decreased
mRNA expression of Slc30a8 (Fig. 2A). In pancreata from
Tcf7l22/2 mice, ZnT8 (Slc30a8) expression was reduced by
44% compared with wild-type control mice (n ¼ 6, Fig. 2B).
This was also replicated in human islets showing a 46% reduc-
tion of SLC30A8 mRNA expression after TCF7L2 silencing
(Fig. 2C). ZnT8 protein expression was also reduced in
INS1 cells after Isl1 and NeuroD1 silencing (Fig. 4A and
D), but not after Pdx1, MafA and Nkx6.1 silencing (Fig. 4B,
C and E).
Finally, expression (mRNA) of Grk5, Ide, Prox1, Kcnk16,
Gipr, Adamts9, Srebf1, Ankrd55, Jazf1, Ccnd2 and Tle1 was
downregulated, whereas expression of Vps26a, Thada, Bcl11a
and Bcl2 was upregulated after Tcf7l2 knockdown (Fig. 5; Sup-
plementary Material, Tables S1 and S2).
DISCUSSION
The current report presents a genetic network controlled by
TCF7L2 in pancreatic islets, providing a comprehensive view
of the molecular mechanisms by which TCF7L2 regulates
glucose metabolism. We demonstrate that TCF7L2 plays a
central role in coordinating the expression of proinsulin and its
subsequent processing to form mature insulin. We also show
that TCF7L2 and ISL1 are key regulators of this transcriptional
network and provide evidence that they regulate MAFA, PDX1,
NEUROD1 and NKX6.1 (Fig. 6). The two prohormone conver-
tases responsible for the processing of proinsulin to mature
insulin were also targets of TCF7L2/ISL1 regulation. These
functions seem to have been highly conserved during evolution
as similar results were obtained in a rat cell line, primary mouse
and human islets. In line with a previous report of an over-
representation of TCF7L2 binding to genes in T2D-associated
loci in HCT116 cells (47), we find that TCF7L2 regulates
several of these genes also in pancreatic islets. Of note,
SLC30A8 (encoding the zinc transporter ZnT8) is a downstream
target of TCF7L2/ISL1 regulation. Zinc is important for the for-
mation of insulin crystals (48), and a common non-synonymous
SNP in the zinc transporter SLC30A8 has been associated with
both T2D (40) and reduced proinsulin-to-insulin conversion
Fig. 4 Continued
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(15). SLC30A8 has previously been identified as a TCF7L2-
target gene in mice (29), a finding now replicated in humans.
Although the mechanisms by which the variant in SLC30A8
increases risk of T2D are not clear, recent data suggest that
reduction in zinc concentrations in the portal vein after
b-cell-specific disruption of Slc30a8 might influence hepatic
insulin clearance (49). If confirmed, this would suggest that
TCF7L2 might influence all key steps in (pro)insulin synthesis,
processing and clearance.
Transcription of proinsulin in humans is under the control of
many glucose responsive TFs that mainly bind a 400 bp con-
served region (50,51). Among the most studied TFs are
MAFA, PDX1 and NEUROD1, all shown here to be transcrip-
tional targets of TCF7L2/ISL1 regulation. In support of this,
ISL1 regulates MAFA expression by directly binding to the
MAFA promoter (52), but its influence on Pdx1, Nkx6.1, Pcsk1
and Pcsk2 expression has not been described to our knowledge.
Together with our recent demonstration of direct binding of
TCF7L2 to the Isl1 promoter (30), these data indicate that
TCF7L2 together with ISL1 forms a master regulatory circuit
influencing both proinsulin expression and processing via regu-
lation ofMafA,Pdx1,Nkx6.1,Pcsk1 andPcsk2. As ISL1 also can
bind and influence the expression of other pancreatic hormones
like glucagon (53) and somatostatin (54), this indicates that
TCF7L2 may also have important regulatory functions in other
islet cell types besides the B-cell. Relatively high expression
of TCF7L2 in a-cells has also been reported in sorted human
pancreatic islet cells (55). A recent study indicated that
NEUROD1 regulates the expression of Ins1 but not Ins2 in
Figure 5. TCF7L2 is a transcriptional regulator of key genes located in T2D-associated loci. mRNA expression measured by QPCR in INS1 cells in Tcf7l2 silenced
versus control cells, (n ¼ 3). Protein expression was measured for two genes, i.e. IDE and BCL2, by western blot in INS1 cells in Tcf7l2 silenced versus controls
(n ¼ 3). Data are represented as mean+SEM. ∗P , 0.05, ∗∗P , 0.01 and ∗∗∗P , 0.001 analyzed by Student’s t-tests (Supplementary Material, Table S1).
Figure 6. Schematic figure of how TCF7L2 functions as a master regulator of
insulin production and processing. Identified TCF7L2-target genes and the
downstream regulatory network responsible for its effect on insulin secretion.
In rodents, as well as human pancreatic islets, ISL1 is a direct target of
TCF7L2. ISL1 regulates proinsulin production and processing via regulation
of PCSK1, PCSK2, SLC30A8, MAFA, PDX1 and NKX6.1. These multiple
targets in key pathways may explain why TCF7L2 has emerged as the gene
showing the strongest association with T2D among common variants. Red
arrows: molecular links observed for the first time. Black arrows: known molecu-
lar links. Direct arrows: direct molecular links. Dash arrows: indirect molecular
links. Blue gene symbols: MODY genes. Purple gene symbols: genes associated
with T2D and/or (pro)insulin traits.
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primary mouseb cells (56), whereas we observed altered expres-
sion of both proinsulin genes and Nkx6.1 in rat cell line.
TCF7L2 may also regulate otherb-cell functions essential for
maintaining GSIS. A perturbation of intracellular [Ca2+] was
observed in one Tcf7l22/2 mouse model, but no major effect
on the expression of Ca2+ channels (29). Here, we find that
although the mRNA levels of several Ca2+ channels important
for GSIS were reduced in Tcf7l2 silenced cells, no changes of
the corresponding proteins were observed either 72 h or 7 days
after Tcf7l2 knockdown. An effect of TCF7L2 on Ca2+ handling
in the B-cell should however not be excluded based upon these
data as these proteins may have a very long half-life in the cell.
An influence on cell viability and regulation of apoptosis are
other well-documented effects of TCF7L2 in pancreatic islets
(11,30,57). The T2D-associated SNP rs7903146 has also been
associated with pancreatic islet morphology, i.e. with reduced
islets density, reduction of islet size and an increased a- to
b-cell ratio in risk-genotype carriers (31). In the same report,
an association between the rs7903146 and GSIS was seen; but
not with insulin content per islet equivalent as shown in our
study. There may be several explanations for these discrepancies
but a large number of high-quality human islets are probably
needed to demonstrate a significant reduction in insulin
content, as the state of the islets can have a large influence on
insulin measurements.
Some recent reports have questioned the dogma that genetic
variants in TCF7L2 exert its major effect on islets (23,58). Boj
et al. recently reported reduced hepatic glucose production in a
liver-specific Tcf7l2 knockout mouse model (23). We and
others have shown an association between the rs7903146
variant and impaired suppression of hepatic glucose production
(7,59,60), but it is not easy to disentangle these effects from the
effects of a reduction in insulin secretion (61). Surprisingly, they
reported no impaired effects on b-cell function in a b-cell-
specific Tcf7l2 knockout mouse (23). This finding is in sharp
contrast with previous reports showing reduced b-cell mass, a
perturbed incretin response and GSIS with reduced insulin
expression (24,27). Although there are no apparent explanations
for these discrepant results they could reflect the application of
B-cell-specific versus whole-islet knockdown strategies, as
TCF7L2 is also expressed in a-cells (55), or a difference
between inducible versus congenital knockdown of TCF7L2,
as Wnt signaling is important for pancreas development (62).
An alternative explanation is a possible compensatory increased
expression of other genes taking over the role of TCF7L2 in theb
cells, in support is the reported lack of regulation of well-known
TCF7L2-target genes, i.e. Axin2 and Sp5 (23). TCF7L2 is
expressed in many tissues besides the pancreas and here is no
doubt that it has central functions in tissues like the brain
(58,63,64), liver (23,65,66), adipose tissue (67,68) and the gut
(58,69). However, given the central role of insulin for mainten-
ance of normal glucose tolerance it is unlikely that an extrapan-
creatic mechanism could exert an effect size of that seen for the
rs7903146 in TCF7L2.
Interestingly, in human islets we observe a negative associ-
ation between TCF7L2 expression and target gene expression
in the proinsulin synthesis pathway (Fig. 1D), but also find that
silencing total expression ofTCF7L2 leads to reduced proinsulin
expression (Fig. 2C). Experimental disruption of TCF7L2 activ-
ity has previously been associated with perturbed islet function
(8,11,24,29–31) but the risk T-allele is suggested to lead to
increased expression of TCF7L2 (Fig. 1C) (7,22,31,32) and per-
turbed GSIS in human islets (Fig. 1A) (2,7–12,31). These seem-
ingly contradictory findings might reflect that total expression of
TCF7L2does not mirror TCF7L2 activity and rather it is the ratio
of activating and inhibiting TCF7L2 isoforms that determine the
activity and hence target gene regulation (33). The rs7903146 is
located near the variable exon 4 (also named 3a), an exon that
have particularly high expression in human islets compared
with other tissues (4). This exon has also been shown to
exhibit regulatory properties, inhibiting TCF7L2-target gene ex-
pression in different cell lines (70,71). Loss of exon 4 also pro-
motes hepatic tumorigenicity (72). Future experiments would
be warranted to investigate if increased expression of exon 4 con-
taining or other isoforms (67) of TCF7L2 may propagate the risk
of T2D conferred by the T-allele of rs7903146.
In summary, in rodents as well as human pancreatic islets,
ISL1 is a direct target of TCF7L2 and ISL1, in turn, regulates pro-
insulin production and processing via regulation of PCSK1,
PCSK2, SLC30A8, MAFA, PDX1 and NKX6.1. Furthermore,
TCF7L2 might also influence hepatic clearance of insulin via
its effect on SLC30A8. Taken together, the current results
provide some explanations for the large impact of TCF7L2 on
the pathogenesis of T2D demonstrating that TCF7L2 is a key
regulator of (pro)insulin synthesis, processing and possibly
clearance.
MATERIALS AND METHODS
RNA sequencing
Sample preparation was made using Illumina TrueSeqTM RNA
sample preparation kit with 1 mg of high-quality total RNA
and was sequenced using a paired-end 101 bp protocol on the
HiSeq2000 platform (Illumina). For INS1 cells, reads were
aligned using Top Hat 2.0.0(73) and Bowtie version: 2.0.0.5
(74) to the rat RGSC3.4 genome assembly. For human islet, 66
samples (all non-diabetic) were sequenced. Sequencing reads
were aligned to the human reference genome (hg19) with
STAR version 2.3.0e (75) and counted using HTseq v0.5.4 and
edgeR (76). The raw sequence reads have been deposited at
European Nucleotide Archive (ERA261116) and at GEO
(GSE50398) for INS1 and human islets, respectively.
Real-time QPCR and western blot
Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen),
cDNA was prepared using RevertAidTM First Strand cDNA Syn-
thesis Kit (Thermo Scientific). QPCR was performed using
TaqMan assays (Supplementary Material, Table S5). mRNA
was measured 48 h (INS1 cells) or 24 h (human islets) after
silencing. For human islets, dispersed human islet cells in
804G-conditioned medium-coated dishes (77) were used.
Protein (15–80 mg) was separated by SDS–PAGE, transferred
to nitrocellulose membranes and detection was made using
SuperSignalWestFemto Chemiluminescent Substrate (Thermo
Scientific). Protein expression was measured 72 h or 7 days
after silencing. Antibodies used can be found in Supplementary
Material, Table S5.
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Statistical analysis
Statistical analyses were performed in IBMw statistics version 21
(IBM Corporation, Armonk, NY, USA). Student’s t-test was used
when two groups were compared and paired t-test was used for
analysis of GSIS, GSPS and TIRFM data.P, 0.05 was regarded
as significant and two-tailedP-values were calculated. FDR of 5%
was used to correct for multiple comparisons. All results are given
as mean+SEM unless otherwise stated.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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